| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | 风湿性
> 干燥综合征 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | We do not communicate with patients directly | International | Regularly | 119025245981 |
| For the authorisation of medicinal products for rare diseases. | 内分泌
> 肾上腺和垂体疾病 | 监管合作伙伴关系
> 为营销授权申报做出贡献 | 100 | National | Rarely | 119052076100 |
| We are engaged in formal consultation processes. | 内分泌
> 糖尿病（1型和2型） | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | Do not know | National | Rarely | 119035824614 |
| Advisory board of Swissmedic. | 癌症
> 癌症：肺 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 1,000 | National | Sometimes | 119061399060 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | 风湿性
> 干燥综合征 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | We do not communicate with patients directly | International | Regularly | 119025245981 |
| This has been achieved, for example, through the submission of concerns regarding access to therapies via umbrella organisations such as ProRaris, as well as through targeted engagement and formal submissions to relevant healthcare stakeholders. | 皮肤
> 血管性水肿 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 100 | National | Sometimes | 119052980204 |
| Via our umbrella organisation HOPOS [Hemato-Onkologische Patientenorganisationen Schweiz - Swiss Umbrella Organisation of Haemato-Oncological Patient Organisations]. | 癌症
> 癌症：血液 | 监管合作伙伴关系
> 与其他医疗保健倡导者 | 1,000 | National | Rarely | 119077844806 |
| To advocate for the establishment of an information policy directed at local authorities. | 癌症
> 癌症：前列腺 | 影响政策和立法
> 影响医疗保健政策和立法 | 100 | Regional | Sometimes | 115056429435 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. | 风湿性
> 干燥综合征 | 影响政策和立法
> 影响医疗保健政策和立法 | We do not communicate with patients directly | International | Regularly | 119025245981 |
| Legislative adaptation through ongoing communication. | 稀有
> 罕见病：儿童/青少年 | 影响政策和立法
> 影响医疗保健政策和立法 | 1,000 | National | Sometimes | 119035891744 |
| Consultation on legislative drafts, and specific requests for assistance — whether material, structural, or socio-economic in nature. | 患者教育
> 患者教育 | 影响政策和立法
> 影响医疗保健政策和立法 | 100 | National | Sometimes | 119035955624 |
| The Swiss Cancer Plan, in collaboration with Oncosuisse and the BAG [Bundesamt für Gesundheit – Federal Office of Public Health]. | 癌症
> 癌症：前列腺 | 影响政策和立法
> 影响医疗保健政策和立法 | 1,000 | National | Regularly | 119044110604 |
| Advocacy representation in relation to the new care legislation. | 神经退行性
> 阿尔茨海默症 | 影响政策和立法
> 影响医疗保健政策和立法 | 100,000 | National | Regularly | 119044141359 |
| Consultation on legislative drafts, and specific requests for assistance — whether material, structural, or socio-economic in nature. | 患者教育
> 患者教育 | 影响政策和立法
> 参与起草公共卫生法规 | 100 | National | Sometimes | 119035955624 |
| Advocacy representation in relation to the new care legislation. | 神经退行性
> 阿尔茨海默症 | 影响政策和立法
> 参与起草公共卫生法规 | 100,000 | National | Regularly | 119044141359 |
| Support with formal cost-approval (reimbursement authorisation) applications and with newly introduced restrictions on treatment options. | 心血管
> 家族性高胆固醇血症（FH） | 影响政策和立法
> 解决医疗保健中的障碍/异常问题 | 100 | National | Sometimes | 119072887138 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | 风湿性
> 干燥综合征 | 定价与可负担性倡导
> 倡导公平的药品定价 | We do not communicate with patients directly | International | Regularly | 119025245981 |
| We work to ensure that effective medicines are available to patients in a fair and timely way, and we explain how pricing and reimbursement decisions directly affect patients and their families in real life. | 癌症
> 癌症：肺 | 定价与可负担性倡导
> 倡导公平的药品定价 | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| Support with reimbursement approvals. | 心血管
> 家族性高胆固醇血症（FH） | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 100 | National | Sometimes | 119072887138 |
| Primarily through public appeals, media coverage, and similar channels [on issues of drug pricing]. | HIV
> HIV | 定价与可负担性倡导
> 参与宣传活动 | 5,000 | National | Rarely | 119035314201 |
| Assisting a family in accessing a medication covered by their insurance. | 神经系统
> 神经纤维瘤病（NF） | 改善访问路径
> 促进公平获取药品/医疗保健 | 100 | Regional | Rarely | 115023088362 |
| This has been achieved, for example, through the submission of concerns regarding access to therapies via umbrella organisations such as ProRaris, as well as through targeted engagement and formal submissions to relevant healthcare stakeholders. | 皮肤
> 血管性水肿 | 改善访问路径
> 促进公平获取药品/医疗保健 | 100 | National | Sometimes | 119052980204 |
| We work to ensure that effective medicines are available to patients in a fair and timely way, and we explain how pricing and reimbursement decisions directly affect patients and their families in real life. | 癌症
> 癌症：肺 | 改善访问路径
> 促进公平获取药品/医疗保健 | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| Participation in European-level policy and regulatory discussions affecting access to medicines for rare and systemic autoimmune diseases. Patient input and advocacy in consultations related to HTA, reimbursement frameworks, and access pathways. Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | 风湿性
> 干燥综合征 | 改善访问路径
> 改善罕见/超罕见疗法的获取途径 | We do not communicate with patients directly | International | Regularly | 119025245981 |
| For the authorisation of medicinal products for rare diseases. | 内分泌
> 肾上腺和垂体疾病 | 改善访问路径
> 改善罕见/超罕见疗法的获取途径 | 100 | National | Rarely | 119052076100 |
| ... Collaboration with European patient platforms and alliances to convey patient perspectives on unmet needs, access delays, and equity in pricing and reimbursement decisions. | 风湿性
> 干燥综合征 | 循证患者意见
> 利用患者洞察来指导决策 | We do not communicate with patients directly | International | Regularly | 119025245981 |
| We speak up to make sure patients' views are properly taken into account when decisions are made about access to new treatments, their cost, and their value. | 癌症
> 癌症：肺 | 循证患者意见
> 利用患者洞察来指导决策 | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| We speak up to make sure patients' views are properly taken into account when decisions are made about access to new treatments, their cost, and their value. | 癌症
> 癌症：肺 | 循证患者意见
> 利用患者洞察来指导决策 | We do not communicate with patients directly | International | Sometimes | 119058458189 |
| This has been achieved, for example, through the submission of concerns regarding access to therapies via umbrella organisations such as ProRaris, as well as through targeted engagement and formal submissions to relevant healthcare stakeholders. | 皮肤
> 血管性水肿 | 循证患者意见
> 将证据和洞察转化为政策建议 | 100 | National | Sometimes | 119052980204 |
| Participation in the RDA [Research Data Alliance]-Forum / CTA [Clinical Trial Authorisation] activities. | 风湿性
> 硬皮病 | 诊断与药品配送
> 协作设计临床试验 | 100 | National | Rarely | 119056569513 |
| Through physicians, hospitals, and participation in PPI [Patient and Public Involvement] meetings. | 癌症
> 癌症：儿童/青少年 | 机构治理
> 在多利益相关方网络中高效协作 | 100 | National | Sometimes | 115032067078 |
| The Swiss Cancer Plan, in collaboration with Oncosuisse and the BAG [Bundesamt für Gesundheit – Federal Office of Public Health]. | 癌症
> 癌症：前列腺 | 机构治理
> 在多利益相关方网络中高效协作 | 1,000 | National | Regularly | 119044110604 |
| We are a non-profit (ZEWO [Zentralstelle für Wohlfahrtsunternehmen - Central Office for Welfare Organisations]-certified) organisation. | 心理健康
> 抑郁症 | 机构治理
> 维持公益或慈善实体的正式地位 | 1,000 | Regional | No | 119063159875 |
| Support for obtaining AI [Assurance Invalidité – Disability Insurance]. | 视觉障碍
> 视觉障碍 | 维护患者权益/提高生活质量
> 保护/改善患者体验 | 100 | Regional | Sometimes | 114996630534 |
互动
行动与倡导
7 提及
